Ramesh Boinpally

AbbVie Inc.

H指数:23

被引数:1,681

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cerebrospinal Fluid and Plasma Concentrations of Atogepant in Humans

人用阿托格普兰的脑脊液和血浆浓度

Clinical and Translational Science

IF2.8

2026-05-270

OAAI

Ubrogepant Plasma and Cerebrospinal Fluid Exposures in Participants With a History of Migraine: Findings From a Phase 1b Open-Label Trial

ubrogepant在具有偏头痛病史的参与者中的血浆和脑脊液暴露：一项1b期开放标签试验的结果

CTS-Clinical and Translational Science

IF2.8

2026-04-210

OAAI

A Human Mass Balance and Metabolism Study of [14C]-Ubrogepant in Healthy Male Adults

[14C]-乌布罗格班特在健康成年男性中的质量平衡和代谢研究

Clinical Pharmacology in Drug Development

IF1.8

2026-01-010

OAAI

Population Pharmacokinetics of Atogepant for the Prevention of Migraine

阿托 gepant 在偏头痛预防中的群体药代动力学

Clinical Pharmacokinetics

IF4

2025-11-120

OAAI

Mass Balance and Metabolism of 14C-Atogepant in Healthy Male Participants: Findings of a Phase 1 Clinical Trial

14C-阿托普兰在健康男性受试者中的质量平衡与代谢：一项I期临床试验结果

Clinical and Translational Science

IF2.8

2025-11-040

OAAI

Exposure-Response Modeling of Monthly Migraine Days for Efficacy of Atogepant in Patients With Episodic or Chronic Migraine

阿托 gepant 在发作性或慢性偏头痛患者中，针对每月偏头痛天数疗效的暴露-反应建模

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2025-11-010

OAAI

Milk and plasma pharmacokinetics of single-dose ubrogepant in healthy lactating women

单剂量ubrogepant在健康哺乳期妇女中的乳汁和血浆药代动力学

HEADACHE

IF4

2025-05-200

Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials

ubrogepant和atogepant对男性和女性偏头痛的疗效: 随机临床试验的二次分析

CEPHALALGIA

IF4.6

2025-02-210

PRE

Clinical Pharmacokinetics of Atogepant in Healthy Japanese and White Adults

NEUROLOGY AND THERAPY

IF4.8

2025-01-040

OAAI

Atogepant: Mechanism of action, clinical and translational science

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2024-01-106

Ubrogepant: Mechanism of action, clinical and translational science

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2024-01-102

Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo- controlled, phase 3 trial

LANCET

IF88.5

2023-09-0146

PRE

Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS phase 3 trial

NEUROLOGY

IF8.5

2023-04-252

PRE

Phase Ib, open-label, fixed-sequence, drug-drug interaction, safety, and tolerability study between atogepant and ubrogepant in participants with a history of migraine

HEADACHE

IF4

2023-01-0511

Randomised clinical trial: effects of MD-7246 on irritable bowel syndrome with diarrhoea

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2022-11-022

OAAI

Linaclotide Reduced Response Time for Irritable Bowel Syndrome With Constipation Symptoms: Analysis of 4 Randomized Controlled Trials

AMERICAN JOURNAL OF GASTROENTEROLOGY

IF7.6

2022-10-123

OAAI

A randomized, multicenter trial assessing the effects of rapastinel compared to ketamine, alprazolam, and placebo on simulated driving performance

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2021-11-075

OAAI

Efficacy of Linaclotide in Reducing Abdominal Symptoms of Bloating, Discomfort, and Pain: A Phase 3B Trial Using a Novel Abdominal Scoring System

AMERICAN JOURNAL OF GASTROENTEROLOGY

IF7.6

2021-06-1129

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study

HEADACHE

IF4

2021-04-0545

OAAI

Atogepant Is Not Associated With Clinically Meaningful Alanine Aminotransferase Elevations in Healthy Adults

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2020-11-2425

OAAI

Ramesh Boinpally

个人简介

教育背景

工作经历

荣誉奖项

研究方向